These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3415201)

  • 21. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 22. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
    Meiler B; Andrich J; Müller T
    Mov Disord; 2008 Jan; 23(1):145-6. PubMed ID: 17987653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duodenal and gastric delivery of levodopa in parkinsonism.
    Kurlan R; Nutt JG; Woodward WR; Rothfield K; Lichter D; Miller C; Carter JH; Shoulson I
    Ann Neurol; 1988 Jun; 23(6):589-95. PubMed ID: 3408240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
    Isacson D; Bingefors K; Kristiansen IS; Nyholm D
    Acta Neurol Scand; 2008 Dec; 118(6):379-86. PubMed ID: 18547273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
    Eggert K; Schrader C; Hahn M; Stamelou M; Rüssmann A; Dengler R; Oertel W; Odin P
    Clin Neuropharmacol; 2008; 31(3):151-66. PubMed ID: 18520982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duodenal levodopa infusion in Parkinson's disease--long-term experience.
    Nilsson D; Nyholm D; Aquilonius SM
    Acta Neurol Scand; 2001 Dec; 104(6):343-8. PubMed ID: 11903087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 33. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 35. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
    Maricle RA; Nutt JG; Carter JH
    Mov Disord; 1995 May; 10(3):329-32. PubMed ID: 7651451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 40. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
    Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
    Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.